
Jan 20 (Reuters) - Boundless Bio Inc BOLD.O:
BOUNDLESS BIO ADVANCES NOVEL KINESIN DEGRADER PROGRAM BBI-940 AND EXTENDS CASH RUNWAY
BOUNDLESS BIO INC: BBI-940 IND ACCEPTED; INITIATION OF FIRST-IN-HUMAN CLINICAL TRIAL ON TRACK FOR FIRST HALF OF 2026
BOUNDLESS BIO INC: PORTFOLIO PRIORITIZATION, INCLUDING DISCONTINUATION OF POTENTIATE TRIAL, EXTENDS OPERATING RUNWAY INTO H2 2028